EDN1 and pulmonary arterial hypertension: Current strategies for the treatment of PAH include targeting deficiencies in NO signaling (PDE-type 5 inhibition), enhancing nucleotide signaling via cAMP PGI2 (prostacyclin analogs), or limiting excessive ET-1 effects (ET receptor blocker).